What’s new

• Service-segment EBITDA margin guidance revised to 25% from over 50% after a cost-accounting change.
• Medical-camp costs are now treated as variable, not fixed, acknowledging patient-turnout risk.
• FY27 service-revenue target of ~₹100 cr remains, supported by ~850 new hires.

Why it matters

The margin cut is a material revision to a core profitability assumption. By reclassifying medical-camp costs, management is admitting the economics of its service model are different from what was previously presented. The sharp hiring push adds risk to the cost base before the revenue materialises.

What we’re watching

• Actual margin realisation versus the new 25% target in upcoming quarters.
• Progress on the ~₹100 crore FY27 revenue goal.
• Economics of the GLP-1 drug partnerships as they scale.

The full read

QMS Medical has cut its service-segment EBITDA margin outlook to 25% from over 50%. The reason is a fundamental rethink of how costs are accounted for. Medical-camp and patient-support expenses are now treated as variable, not fixed. This is an admission that patient turnout carries real risk. The revision comes alongside an aggressive scaling push, with the company adding nearly 850 employees and frontloading technology spend, which is squeezing profits now. Despite the margin reset, the revenue target holds: management is aiming for ~₹100 crore in service revenue in FY27, with GLP-1 drug partnerships expected to lift profitability as operations mature. The new accounting gives a clearer picture of the business's economics, but it confirms the service segment is far less profitable than previously guided.

Primary source: NSE